355 related articles for article (PubMed ID: 29181548)
1. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
2. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
3. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
Alvarez-Larrán A; Bellosillo B; Pereira A; Kerguelen A; Hernández-Boluda JC; Martínez-Avilés L; Fernández-Rodríguez C; Gómez M; Lombardía L; Angona A; Ancochea A; Senín A; Longarón R; Navarro B; Collado M; Besses C
Am J Hematol; 2014 May; 89(5):517-23. PubMed ID: 24458835
[TBL] [Abstract][Full Text] [Related]
4. Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.
Tiong IS; Casolari DA; Nguyen T; Van Velzen MJ; Ambler K; D'Andrea RJ; Ross DM
Blood Cancer J; 2016 Aug; 6(8):e459. PubMed ID: 27540717
[No Abstract] [Full Text] [Related]
5. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
6. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
[TBL] [Abstract][Full Text] [Related]
7. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
[TBL] [Abstract][Full Text] [Related]
8. Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.
Luque Paz D; Chauveau A; Boyer F; Buors C; Samaison L; Cottin L; Seegers V; Férec C; Le Maréchal C; Gueguen P; Lippert E; Ianotto JC; Ugo V
Genes Chromosomes Cancer; 2017 May; 56(5):354-362. PubMed ID: 27997717
[TBL] [Abstract][Full Text] [Related]
9. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
10. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
11. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
[TBL] [Abstract][Full Text] [Related]
14. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
[TBL] [Abstract][Full Text] [Related]
15. JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia.
Randi ML; Ruzzon E; Tezza F; Scapin M; Duner E; Scandellari R; Fabris F
Aging Clin Exp Res; 2011 Feb; 23(1):17-21. PubMed ID: 21499015
[TBL] [Abstract][Full Text] [Related]
16. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
[TBL] [Abstract][Full Text] [Related]
17. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
18. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
Alvarez-Larrán A; Senín A; Fernández-Rodríguez C; Pereira A; Arellano-Rodrigo E; Gómez M; Ferrer-Marin F; Martínez-López J; Camacho L; Colomer D; Angona A; Navarro B; Cervantes F; Besses C; Bellosillo B; Hernández-Boluda JC
Br J Haematol; 2017 Sep; 178(5):764-771. PubMed ID: 28542718
[TBL] [Abstract][Full Text] [Related]
19. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
Guglielmelli P; Barosi G; Pieri L; Antonioli E; Bosi A; Vannucchi AM
Haematologica; 2009 Jan; 94(1):144-6. PubMed ID: 19042918
[No Abstract] [Full Text] [Related]
20. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
